NCT04570501

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in patients with COVID 19.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Angiotensin-(1-7)	Ang (1-7) administered by continuous intravenous (IV) infusion
DRUG	Placebo	Placebo (normal saline) administered by continuous intravenous (IV) infusion

Timeline

• Start date: 2022-02-01
• Primary completion: 2022-08-01
• Completion: 2022-08-01
• First posted: 2020-09-30
• Last updated: 2022-03-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study